Down 10%: Peregrine Hits the Brakes

After an incredible week that saw shares of Peregrine Pharmaceuticals appreciate a surprising 80% on Monday, shares of this biotech took a 10% haircut today. Why the drop? In this video, health care analyst Max Macaluso discusses today's decline and offers his opinion of what investors should watch in the coming weeks.

What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.

The article Down 10%: Peregrine Hits the Brakes originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.